Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-083 in Charcot-Marie-Tooth Disease Types 1 and X
NCT03124459Phase 2Terminated
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efmitermant alfa in Charcot-Marie-Tooth disease type 1 (CMT1), Charcot-Marie-Tooth disease type X (CMTX). Started Jul 2017; status: terminated.
02
Drugs
efmitermant alfa
03
Conditions
Charcot-Marie-Tooth disease type 1 (CMT1)Charcot-Marie-Tooth disease type X (CMTX)
Beyond the preview
Go deeper on NCT03124459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03124459.